North Carolina State University is seeking a commercial licensee to commercialize a platelet membrane- coated nonparticulate platform for the enhance treatment of multiple myeloma and thrombus.
Multiple Myeloma is one of the most frequently occurred hematological cancers. Although there has been significant advances radiation therapy chemotherapy and stem cell implantation, the treatment of MM remains a challenge. The non-specific distribution and short circulation time after proteasome inhibitor combination regimens sometimes results in side effects and has limitations in application. In addition, there is very often the emergence of thrombus. Therefore, there is a need for a new delivery mechanism for proteasome inhibitors such as bortezomib.
Researchers at North Carolina State University have developed a platelet membrane coated nanoparticulate platform for the targeted delved of bortezomib at the myeloma site. A core-shell structured nanocarrier with a platelet membrane wrapped in the surface transports the bortezomib and tPA to the desired location. After intravenous injection, the nanoparticles accumulate at the myeloma site through sequential targeting of the bone microenvironment.
- Targeted delivery of multiple myeloma drugs
- Reduced side effects from multiple myeloma drugs
- Minimization of thrombus formation during treatment
Related Patent Information
A patent application related to this invention has been filed.
About the Lead Inventor
Dr. Zhen Gu obtained Ph.D. at the University of California, Los Angeles, under the guidance of Prof. Yi Tang in the Department of Chemical and Biomolecular Engineering. He was a postdoctoral associate working with Prof. Robert Langer at MIT and Harvard Medical School during 2010 to 2012. He is currently an Associate Professor and founding Director of the Translational Innovation (TraIn) Professional Science Master program in the Joint Department of Biomedical Engineering at the University of North Carolina at Chapel Hill and North Carolina State University. He also holds joint positions in the Eshelman School of Pharmacy and Department of Medicine at UNC. His group studies controlled drug delivery, bio-inspired materials and nanobiotechnology. Prof. Gu is the recipient of the Sloan Research Fellowship (2016), Pathway Award (2015) and Junior Faculty Award (2014) of the American Diabetes Association (ADA), Young Innovator Award in Cellular and Molecular Engineering of the Biomedical Engineering Society (BMES, 2015) and the Sigma Xi Young Faculty Research Award (2014). MIT Technology Review listed him in 2015 as one of the global top innovators under the age of 35 (TR35). GOOD Magazine listed him in 2016 as one of GOOD 100- “100 individuals who are improving the world through creativity and innovation”.